Jpmorgan Chase & CO Aerovate Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Aerovate Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 5,991 shares of AVTE stock, worth $15,756. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,991
Previous 5,827
2.81%
Holding current value
$15,756
Previous $9,000
33.33%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding AVTE
# of Institutions
78Shares Held
28.1MCall Options Held
116KPut Options Held
26.6K-
Ra Capital Management, L.P. Boston, MA9.19MShares$24.2 Million0.27% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA3.76MShares$9.89 Million0.74% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA2.24MShares$5.89 Million0.61% of portfolio
-
Atlas Venture Life Science Advisors, LLC1.8MShares$4.73 Million0.46% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY1.41MShares$3.71 Million0.05% of portfolio
About Aerovate Therapeutics, Inc.
- Ticker AVTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,448,100
- Market Cap $64.3M
- Description
- Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...